Abstract:Transforming growth factor-β (TGF-β) inhibits the proliferation of epithelial cells by altering the expression or function of various components of the cell cycle machinery. Expression of one of these components, cyclin A, is inhibited by TGF-β treatment. We have identified a 760-base pair fragment of the human cyclin A gene promoter that is sufficient to confer TGF-β responsiveness. Using this promoter fragment, we have developed a cyclin A-based luciferase reporter assay that quantitates the growth inhibitory effect of TGF-β in transient transfection assays. This assay was used to determine which domains of the type I (RI) and type II (RII) receptors were required for the antiproliferative effect of TGF-β. In parallel, the functionality of chimeric receptors, between RI and RII (RI-RII or RII-RI), was tested for TGF-β effect on gene expression using a reporter assay based on the plasminogen activator inhibitor type 1 (PAI-1) promoter. We found that TGF-β-induced inhibition of cyclin A expression was absent in RI or RII-deficient Mv1Lu cells and that this response was restored by expression of wild-type type I or type II receptors in these cells. Furthermore, expression of a single chimeric receptor, either RI-RII or RII-RI, did not confer cyclin A regulation by TGF-β. However, expression of two reciprocal chimeras (RI-RII and RII-RI) resulted in growth inhibition, similarly to wild-type receptors. In addition, chimeric receptors as well as mutant receptors with a deleted cytoplasmic domain and kinase-negative receptors inhibited TGF-β responsiveness in the cyclin A reporter assay in a dominant negative fashion. Finally, in both receptor types, the juxtamembrane domain preceding the kinase domain was essential for receptor function but the cytoplasmic tail was dispensable. Our results suggest that a functional TGF-β receptor complex is required for TGF-β-dependent down-regulation of cyclin A gene expression and illustrate the identical receptor requirements for TGF-β-induced growth inhibition and gene expression. Transforming growth factor-β (TGF-β) inhibits the proliferation of epithelial cells by altering the expression or function of various components of the cell cycle machinery. Expression of one of these components, cyclin A, is inhibited by TGF-β treatment. We have identified a 760-base pair fragment of the human cyclin A gene promoter that is sufficient to confer TGF-β responsiveness. Using this promoter fragment, we have developed a cyclin A-based luciferase reporter assay that quantitates the growth inhibitory effect of TGF-β in transient transfection assays. This assay was used to determine which domains of the type I (RI) and type II (RII) receptors were required for the antiproliferative effect of TGF-β. In parallel, the functionality of chimeric receptors, between RI and RII (RI-RII or RII-RI), was tested for TGF-β effect on gene expression using a reporter assay based on the plasminogen activator inhibitor type 1 (PAI-1) promoter. We found that TGF-β-induced inhibition of cyclin A expression was absent in RI or RII-deficient Mv1Lu cells and that this response was restored by expression of wild-type type I or type II receptors in these cells. Furthermore, expression of a single chimeric receptor, either RI-RII or RII-RI, did not confer cyclin A regulation by TGF-β. However, expression of two reciprocal chimeras (RI-RII and RII-RI) resulted in growth inhibition, similarly to wild-type receptors. In addition, chimeric receptors as well as mutant receptors with a deleted cytoplasmic domain and kinase-negative receptors inhibited TGF-β responsiveness in the cyclin A reporter assay in a dominant negative fashion. Finally, in both receptor types, the juxtamembrane domain preceding the kinase domain was essential for receptor function but the cytoplasmic tail was dispensable. Our results suggest that a functional TGF-β receptor complex is required for TGF-β-dependent down-regulation of cyclin A gene expression and illustrate the identical receptor requirements for TGF-β-induced growth inhibition and gene expression.

Transforming Growth Factor-β (TGF-β)-induced Down-regulation of Cyclin A Expression Requires a Functional TGF-β Receptor Complex

TACE-Mediated Ectodomain Shedding of the Type I TGF-β Receptor Downregulates TGF-β Signaling

TACE-Mediated Ectodomain Shedding of the Type I TGF-b Receptor Downregulates TGF-b Signaling

Transforming Growth Factor β Inhibits Platelet Derived Growth Factor-Induced Vascular Smooth Muscle Cell Proliferation via Akt-Independent, Smad-Mediated Cyclin D1 Downregulation

Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor.

Transforming Growth Factor-β Stimulates Cyclin D1 Expression Through Activation of Β-Catenin Signaling in Chondrocytes

Reduced Expression of Transforming Growth Factor β Type I Receptor Contributes to the Malignancy of Human Colon Carcinoma Cells

[Nuclear Factor I-C Inhibits Platelet-Derived Growth Factor-Induced Enhancement of Dermal Fibroblast Sensitivity to TGF-β].

Resistance to transforming growth factor–beta occurs in the presence of normal Smad activation

Tumor Necrosis Factor Α Inhibits Cyclin A Expression and Retinoblastoma Hyperphosphorylation Triggered by Insulin-like Growth Factor-I Induction of New E2F-1 Synthesis

Ligand-independent Activation of Transforming Growth Factor (TGF) Β Signaling Pathways by Heteromeric Cytoplasmic Domains of TGF-β Receptors

Regulation of Fibroblastic and Epithelial Cell Function by Transforming Growth Factors

A Kinase Subdomain of Transforming Growth Factor-Beta (Tgf-Beta) Type I Receptor Determines the Tgf-Beta Intracellular Signaling Specificity

Transforming Growth Factor Β Signal Transduction

Cell type-dependent control of NF-Y activity by TGF-β

Transforming growth factor-β receptors: versatile mechanisms of ligand activation

Functional Characterization of Transforming Growth Factor Β Signaling in Smad2- and Smad3-deficient Fibroblasts*

Distinct roles of transforming growth factor-β signaling and transforming growth factor-β receptor inhibitor SB431542 in the regulation of p21 expression

Controlling TGF-β Signaling

Transforming Growth Factor-β Receptor Type I and Type II Expression During Murine Hair Follicle Development and Cycling

Transforming Growth Factor-Β-mediated Mast Cell Migration Depends on Mitogen-Activated Protein Kinase Activity